Table 2.
Age group in 2020 | Women affected by a 6-month rolling delay to screeninga | Estimated number of women with CIN2/3 in population | Excess diagnoses of cervical cancer | Excess rates per 100,000 affected | Excess rates per 100,000 population |
---|---|---|---|---|---|
25–29 | 1,533,957 | 45,772b | 55 | 3.6 | 2.9 |
30–34 | 1,329,927 | 18,952b | 47 | 3.6 | 2.5 |
35–39 | 1,365,366 | 21,846 | 76 | 5.6 | 4.1 |
40–44 | 1,238,154 | 19,810 | 129 | 10.4 | 7.5 |
45–49 | 1,316,637 | 21,066 | 137 | 10.4 | 7.3 |
50–54 | 1,698,585 | 8493 | 76 | 4.5 | 3.9 |
55–59 | 1,284,705 | 6424 | 58 | 4.5 | 3.1 |
60–64 | 932,160 | 4661 | 51 | 5.5 | 3.2 |
Total | 10,699,491 | 147,024 | 630 | 5.9 | 4.3 |
a Women who undergo screening in one screening round of 3 or 5 years, depending on age, estimated from the NHS Cervical Screening Programme statistics for years 2018–2019.
bRate of CIN2/3 in the population adjusted for proportion vaccinated.